Pulmonary hypertension treatment can help slow disease progression, ease symptoms, and improve quality of life for people with the disease.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug ...

PAH is a serious condition that can affect people of all ages. It occurs when the tiny arteries in the lungs become thickened and narrowed, which causes reduced blood flow through the lungs. This ...

The FDA has approved an update to the prescribing information for Merck‘s PAH treatment Winrevair (sotatercept-csrk).

The FDA has expanded the approval of Winrevair to include treatment of adults with PAH WHO Group 1 to improve exercise capacity and WHO FC, and reduce the risk of clinical worsening events including ...

Sotatercept-csrk is approved for improving exercise capacity and reducing clinical worsening in PAH patients, following FDA ...

The FDA approved a label update for Winrevair to include that it lowers the risk for clinical worsening events in adults with ...

The addition of sotatercept, an activin-signaling inhibitor, to background therapy results in a lower risk for clinical worsening among adults with pulmonary arterial hypertension who were diagnosed ...

Pulmonary hypertension (PH) and pulmonary arterial hypertension (PAH) prevalence is higher among Medicaid beneficiaries, with significant racial and ethnic disparities, particularly affecting Black ...

Adults with pulmonary arterial hypertension using vs. not using GLP-1 receptor agonists had significantly lower relative ...

WINREVAIR significantly reduced the risk of major morbidity and mortality events, the primary endpoint, in adults with PAH (Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality ...